Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-57864

ABSTRACT: Gene expression in diploid and evolved tetraploid RPE-1 and BJ-1 cells

OTHER RELATED OMICS DATASETS IN: PRJNA248291

PROVIDER: E-GEOD-57864 | ExpressionAtlas | 2015-08-04

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-GEOD-57864-analysis-methods.tsv	Tabular
	E-GEOD-57864-atlasExperimentSummary.Rdata	Rdata
	E-GEOD-57864-configuration.xml	Xml
	E-GEOD-57864-percentile-ranks.tsv	Tabular
	E-GEOD-57864.condensed-sdrf.tsv	Tabular

Items per page:

1 - 5 of 53

Similar Datasets

Biomarks of Resistance to Cetuximab in Colorectal Cancer

Project description:Interventions: A group:Before using cetuximab;B group:After progression of disease:no Primary outcome(s): KRAS gene sequence;NRAS gene sequence;BRAF gene sequence;PIK3CA gene sequence;EGFR gene sequence;EGFR gene copy numbers;EGFR expression;Her2 expression;c-Met expression;PTEN expression Study Design: historical control

| 2671639 | ecrin-mdr-crc

TR study of ‘multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer&quot

Project description:Primary outcome(s): Cancer-related gene alteration, expression of protein, and expression of RNA

| 2645675 | ecrin-mdr-crc

Colorectal Cancer Screening Validation Study

Project description:The purpose of this study is to evaluate the gene expression patterns from colorectal mucosal cells collected through the use of a standard anoscope and cytology brush. Patients will include those scheduled for routine colonoscopy procedures and those with confirmed colorectal cancer.

| 2058649 | ecrin-mdr-crc

TR study of ‘A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer (BRAVERY study)&quot

Project description:Primary outcome(s): cancer-related gene alteration, gene expression, microsatellite instability, BRAF mutant allele frequency

| 2646701 | ecrin-mdr-crc

Transcription profiling of human hepatocytes treated with doxorubicin and Trovafloxacin, super-series of E-GEOD-11940 and E-GEOD-11941

Project description:This SuperSeries is composed of the following subset Series:; GSE11940: Topoisomerase II inhibition involves characteristic chromosomal expression patterns: Doxorubicin study; GSE11941: Topoisomerase II inhibition involves characteristic chromosomal expression patterns: Trovafloxacin study Experiment Overall Design: Refer to individual Series

2008-10-26 | E-GEOD-11942 | biostudies-arrayexpress

Gene expression analaysis of the lateral spreading tumor

Project description:Primary outcome(s): Gene expression of targeted genes

| 2625389 | ecrin-mdr-crc

TR study of ‘A multi-center proof-of-concept phase2 study of encorafenib + binimetinib + cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (BIGBANG study)&quot

Project description:Primary outcome(s): Cancer related genome analysis, gene expression and molecular characterization analysis

| 2647002 | ecrin-mdr-crc

The clinical study to investigate between immune and gene-expression profile and clinical significance

Project description:Primary outcome(s): The clinical significance of immune and gene-expression profile in colorectal cancer

| 2659791 | ecrin-mdr-crc

TR accompanied with the study titled A multicenter phase II study of Nivolumab monotherapy in recurrent and/or metastatic gastrointestinal cancer patients with high Tumor Mutation Burden (TMB-H).

Project description:Primary outcome(s): 1. Evaluation of genome abnormality and gene expression by omics analysis of tumor etc. 2. TCR repertoire analysis and RNA expression analysis etc. of T cells in tumor tissue and peripheral blood. 3. Prediction and identification of tumor neo-antigen and evaluation of immunogenicity etc. 4. Analyze ctDNA(16S rRNA PCR) and feces of patients with advanced solid malignancies over time to profile and monitor cancer-related genomic alterations 5. Assessment of the relationship between the analysis above and clinical pathological features or therapeutic efficacy etc.

| 2648665 | ecrin-mdr-crc

Analysis of predictive biomarker and analysis of correlations between toxicities and SNPs that can be related to pharmacokinetics, in trifluridine/tipiracil hydrochloride therapy for previously fluoropyrimidine-treated elderly patients with unresectable or recurrent colorectal cancer

Project description:Interventions: Nucleic acid from tumor tissues and serum SNPs Primary outcome(s): 1. Tissue biomarkers including mutation, gene expression, and DNA methylation that correlate with efficacy from trifluridine/tipiracil hydrochloride therapy 2. Serum biomarkers including mutation, gene expression, and DNA methylation that correlate with efficacy from trifluridine/tipiracil hydrochloride therapy 3. SNPs that correlate with toxicities from trifluridine/tipiracil hydrochloride therapy Study Design: Single arm Non-randomized

| 2637006 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data